Get the Stockscreener App
5.10
7.82%
0.37
After Hours:
5.18
0.08
+1.57%
Shattuck Labs Inc stock is traded at $5.10, with a volume of 1.50M.
It is up +7.82% in the last 24 hours and up +42.86% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$4.73
Open:
$4.56
24h Volume:
1.50M
Relative Volume:
2.50
Market Cap:
$322.73M
Revenue:
$2.72M
Net Income/Loss:
$-85.08M
P/E Ratio:
-2.6425
EPS:
-1.93
Net Cash Flow:
$-70.93M
1W Performance:
+26.24%
1M Performance:
+42.86%
6M Performance:
+229.03%
1Y Performance:
+311.29%
1-Day Range:
$4.56
$5.20
1-Week Range:
$3.81
$5.20
52-Week Range:
$0.6922
$5.20
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
5.10 | 299.31M | 2.72M | -85.08M | -70.93M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights - Investing News Network
Shattuck Labs (STTK) Anticipates Strong Cash Runway Through 2029 - GuruFocus
Shattuck Labs (STTK) Reports Q4 Revenue and Clinical Trial Progr - GuruFocus
Shattuck Labs 10-K: $1.0M Revenue, $(0.70) EPS on FY Loss Improvement - TradingView
Shattuck Labs Q4 net loss narrows on lower R&D spend - TradingView
Shattuck Labs (NASDAQ: STTK) cuts 2025 R&D spend, funds operations into 2029 - Stock Titan
Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Down 14.7% in February - MarketBeat
STTK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Shattuck Labs at TD Cowen Conference: Strategic Insights in IBD Treatment - Investing.com Canada
Aug PreEarnings: Will Shattuck Labs Inc benefit from sector rotation2025 AllTime Highs & High Conviction Buy Zone Alerts - baoquankhu1.vn
STTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
STTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Shattuck Labs Announces Participation in Upcoming March Investor Conferences - Investing News Network
Shattuck Labs CEO heads to Boston and Miami for March investor talks - Stock Titan
STTKShattuck Labs, Inc. Latest Stock News & Market Updates - Stock Titan
Shattuck Labs Just Shocked Wall Street: Is STTK the Next Sleeper Biotech Rocket or Total Trap? - AD HOC NEWS
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $6.20 Average Price Target from Analysts - Defense World
Market Recap: Is Shattuck Labs Inc. stock positioned well for digital economyCEO Change & Smart Money Movement Tracker - mfd.ru
Can Shattuck Labs Inc. deliver consistent dividendsPortfolio Return Summary & Free Expert Approved Momentum Trade Ideas - mfd.ru
What’s the RSI of Shattuck Labs Inc. stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - mfd.ru
What is the cash position of Shattuck Labs Inc.July 2025 Weekly Recap & Weekly High Momentum Picks - mfd.ru
Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Why is Shattuck Labs Inc. stock going downTrade Entry Summary & Fast Momentum Entry Tips - mfd.ru
Is Shattuck Labs Inc.’s ROIC above industry averageQuarterly Portfolio Review & Weekly Top Gainers Trade List - mfd.ru
Fed Watch: Will Shattuck Labs Inc benefit from green energy policiesEarnings Miss & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium - marketscreener.com
Breakout Zone: Why is Shattuck Labs Inc stock going downAnalyst Downgrade & Advanced Technical Analysis Signals - baoquankhu1.vn
Shattuck Labs to Participate in Immunology Symposium - Intellectia AI
Inside Shattuck Labs' Piper Sandler immunology fireside chat - stocktitan.net
Shattuck Labs Insider Buyers Net US$637k Despite 12% Stock Decline - simplywall.st
Shattuck Labs Sets Earlier Date for 2026 Annual Meeting - TipRanks
Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Shattuck Labs (STTK) Price Target Increased by 55.36% to 7.40 - Nasdaq
Shattuck Labs, Inc. (NASDAQ:STTK) Sees Significant Increase in Short Interest - MarketBeat
Piper Sandler Initiates Coverage of Shattuck Labs (STTK) with Overweight Recommendation - Nasdaq
Piper Sandler Initiates Coverage on STTK with Overweight Rating - GuruFocus
Shattuck earns new Overweight at Piper Sandler ahead of upcoming catalysts - Seeking Alpha
Piper Sandler Initiates Coverage on Shattuck Labs With Overweight Rating, $15 Price Target - marketscreener.com
Shattuck Labs initiated with an Overweight at Piper Sandler - TipRanks
Piper Sandler initiates Shattuck Labs stock with Overweight rating By Investing.com - Investing.com Canada
Will DAKT stock hit new highs in YEAR2025 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Shattuck Labs Launches $75 Million At-The-Market Offering - TipRanks
Shattuck Labs Inc enters $75 million common stock sales agreement with Leerink Partners - marketscreener.com
Shattuck Labs Inc Enters $75 Million Common Stock Sales Agreement With Leerink Partners - TradingView
Earnings Risk: Why is Shattuck Labs Inc stock going downJuly 2025 Setups & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is Shattuck Labs Inc.’s growth already priced inJuly 2025 Setups & Growth Oriented Trade Recommendations - bollywoodhelpline.com
Resistance Check: Is Shattuck Labs Inc stock a value trapQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Update - Defense World
Shattuck Labs: "Hold" On Oncology Exit And Competitive TL1A/DR3 Pathway Pivot (STTK) - Seeking Alpha
Shattuck Labs (STTK) Price Target Increased by 16.67% to 4.76 - Nasdaq
Shattuck Labs Files $200 Million Mixed Shelf - marketscreener.com
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ashiya Mona | Director |
Aug 25 '25 |
Buy |
0.87 |
6,306,127 |
5,471,826 |
5,255,106 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):